Systemic, local, and sclerotherapy drugs: What do we know about drug prescribing in vascular anomalies?
Kasabach-Merritt phenomenon
drug safety
hemangiomas
hematology (nonmalignant)
hematology/oncology
patient safety
pediatric hematology/oncology
pharmacology
pharmacovigilance
vascular malformations
vascular tumors
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
revised:
08
08
2021
received:
09
05
2021
accepted:
31
08
2021
pubmed:
2
10
2021
medline:
16
4
2022
entrez:
1
10
2021
Statut:
ppublish
Résumé
Off-label drug prescribing, frequent in the treatment of vascular anomalies (VA), relies on the quality of the literature reporting drug efficacy and safety. Our objective is to review the level of evidence (LOE) surrounding drug use in VA, which is more prevalent in pediatric care. A list of drugs used in VA was created with a literature review in July 2020. For each drug listed, the article displaying the highest LOE was determined and then compared between efficacy/safety data, routes of administration, pharmacological categories and a subset of VA. The influence of research quality on study results was also explored. The median LOE for the 74 drugs identified poor methodological quality, with a predominance of retrospective studies or case reports. Drug safety is currently inadequately reported. This is alarming as many treatments display significant safety concerns. Also, current literature displays major publication bias that probably leads to overestimation of drug efficacy in VA.
Substances chimiques
Pharmaceutical Preparations
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e29364Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Ricci KW. Advances in the medical management of vascular anomalies. Semin Intervent Radiol. 2017;34(3):239-249.
Adams DM, Ricci KW. Vascular anomalies: diagnosis of complicated anomalies and new medical treatment options. Hematol Oncol Clin North Am. 2019;33(3):455-470.
Kleiber N, Gariépy-Assal L, Coulombe J, et al. Off-label use and safety of drug use in vascular anomalies. Dermatology. 2021;237(4):649-657.
ISSVA Classification of Vascular Anomalies 2018. International Society for the Study of Vascular Anomalies. 2018.
The Oxford 2011 Levels of Evidence. Oxford Centre for Evidence-Based Medicine. 2011.
Thai T, Wang C-Yu, Chang C-Y, Brown J. Central nervous system effects of oral propranolol for infantile hemangioma: a systematic review and meta-analysis. J Clin Med. 2019;8(2):268.
Xu P, Yu Q, Huang H, Zhang W, Li W. A self-controlled study of intralesional injection of diprospan combined with topical timolol cream for treatment of thick superficial infantile hemangiomas. Dermatol Ther. 2018;31(3):e12595.
Dupuis-Girod S, Ambrun A, Decullier E, et al. Effect of bevacizumab nasal spray on epistaxis duration in hereditary hemorrhagic telangectasia: a randomized clinical trial. JAMA. 2016;316(9):934-942.
Riss D, Burian M, Wolf A, Kranebitter V, Kaider A, Arnoldner C. Intranasal submucosal bevacizumab for epistaxis in hereditary hemorrhagic telangiectasia: a double-blind, randomized, placebo-controlled trial. Head Neck. 2015;37(6):783-787.
Whitehead KJ, Sautter NB, Mcwilliams JP, et al. Effect of topical intranasal therapy on epistaxis frequency in patients with hereditary hemorrhagic telangiectasia: a randomized clinical trial. JAMA. 2016;316(9):943-951.
Tremaine AM, Armstrong J, Huang Yu-C, et al. Enhanced port-wine stain lightening achieved with combined treatment of selective photothermolysis and imiquimod. J Am Acad Dermatol. 2012;66(4):634-641.
Giguère CM, Bauman NM, Sato Y, et al. Treatment of lymphangiomas with OK-432 (Picibanil) sclerotherapy: a prospective multi-institutional trial. Arch Otolaryngol Head Neck Surg. 2002;128(10):1137-1144.
Gao Z, Zhang Yi, Li W, Shi C. Effectiveness and safety of polidocanol for the treatment of hemangiomas and vascular malformations: a meta-analysis. Dermatol Ther. 2018;31(1). https://doi.org/10.1111/dth.12568
Malik MA, Menon P, Rao KLN, Samujh R. Effect of propranolol vs prednisolone vs propranolol with prednisolone in the management of infantile hemangioma: a randomized controlled study. J Pediatr Surg. 2013;48(12):2453-2459.
Lou Y, Peng W-J, Cao Yi, Cao D-S, Xie J, Li H-H. The effectiveness of propranolol in treating infantile haemangiomas: a meta-analysis including 35 studies. Br J Clin Pharmacol. 2014;78(1):44-57.
Marqués L, Núñez-Córdoba JM, Aguado L, et al. Topical rapamycin combined with pulsed dye laser in the treatment of capillary vascular malformations in Sturge-Weber syndrome: phase II, randomized, double-blind, intraindividual placebo-controlled clinical trial. J Am Acad Dermatol. 2015;72(1):151-158.e1.
Dupuis-Girod S, Fargeton A-E, Grobost V, et al. Efficacy and safety of a 0.1% tacrolimus nasal ointment as a treatment for epistaxis in hereditary hemorrhagic telangiectasia: a double-blind, randomized, placebo-controlled, multicenter trial. J Clin Med. 2020;9(5):1262.
Lin Z, Zhang B, Yu Z, Li H. The effectiveness and safety of topical β-receptor blocker in treating superficial infantile haemangiomas: a meta-analysis including 20 studies. Br J Clin Pharmacol. 2020;86(2):199-209.
Gaillard S, Dupuis-Girod S, Boutitie F, et al. Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease. J Thromb Haemost. 2014;12(9):1494-1502.
Liu X, Li J, Qu X, et al. Clinical outcomes for systemic corticosteroids versus vincristine in treating kaposiform hemangioendothelioma and tufted angioma. Medicine (Baltimore). 2016;95(20):e3431.
Zaher H, Rasheed H, El-Komy MM, et al. Propranolol versus captopril in the treatment of infantile hemangioma (IH): a randomized controlled trial. J Am Acad Dermatol. 2016;74(3):499-505.
Mehta A, Bajaj MS, Pushker N, et al. To compare intralesional and oral propranolol for treating periorbital and eyelid capillary hemangiomas. Indian J Ophthalmol. 2019;67(12):1974-1980.
Léauté-Labrèze C, De La Roque ED, Hubiche T, Boralevi F, Thambo J-B, Taïeb A. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358(24):2649-2651.
Méndez-Echevarría A, Fernandez-Prieto A, De La Serna O, et al. Acute lung toxicity after intralesional bleomycin sclerotherapy. Pediatrics. 2018;141(1):e20161787.
Barlow CF, Priebe CJ, Mulliken JB, et al. Spastic diplegia as a complication of interferon Alfa-2a treatment of hemangiomas of infancy. J Pediatr. 1998;132(3 Pt 1):527-530.
Russell TB, Rinker EK, Dillingham CS, Givner LB, Mclean TW. Pneumocystis jirovecii pneumonia during sirolimus therapy for kaposiform hemangioendothelioma. Pediatrics. 2018;141(Suppl 5):S421-S424.
Léauté-Labrèze C, Harper JI, Hoeger PH. Infantile haemangioma. Lancet. 2017;390(10089):85-94.
Duffau P, Lazarro E, Viallard J-F. [Hereditary hemorrhagic telangiectasia]. Rev Med Interne. 2014;35(1):21-27.
Janmohamed SR, Van Oosterhout M, De Laat PCJ, Van Rosmalen J, Madern GC, Oranje AP. Scoring the therapeutic effects of oral propranolol for infantile hemangioma: a prospective study comparing the Hemangioma Activity Score (HAS) with the Hemangioma Severity Scale (HSS). J Am Acad Dermatol. 2015;73(2):258-263.
Hoag JB, Terry P, Mitchell S, Reh D, Merlo CA. An epistaxis severity score for hereditary hemorrhagic telangiectasia. Laryngoscope. 2010;120(4):838-843.
Drolet BA, Trenor CC, Brandão LR, et al. Consensus-derived practice standards plan for complicated kaposiform hemangioendothelioma. J Pediatr. 2013;163(1):285-291.
Koren G. Bias against the null hypothesis in maternal-fetal pharmacology and toxicology. Clin Pharmacol Ther. 1997;62(1):1-5. https://doi.org/10.1016/s0009-9236(97)90144-2
Le Sage S, David M, Dubois J, et al. Efficacy and absorption of topical sirolimus for the treatment of vascular anomalies in children: a case series. Pediatr Dermatol. 2018;35(4):472-477.
Adams DM, Trenor CC, Hammill AM, et al. Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies. Pediatrics. 2016;137(2):e20153257.
Hammer J, Seront E, Duez S, et al. Sirolimus is efficacious in treatment for extensive and/or complex slow-flow vascular malformations: a monocentric prospective phase II study. Orphanet J Rare Dis. 2018;13(1):191.
Venot Q, Blanc T, Rabia SH, et al. Targeted therapy in patients with PIK3CA-related overgrowth syndrome. Nature. 2018;558(7711):540-546.
Mizuno T, Emoto C, Fukuda T, Hammill AM, Adams DM, Vinks AA. Model-based precision dosing of sirolimus in pediatric patients with vascular anomalies. Eur J Pharm Sci. 2017;109S:S124-S131.
Harvey JA, Nguyen H, Anderson KR, et al. Pain, psychiatric comorbidities, and psychosocial stressors associated with Klippel-Trenaunay syndrome. J Am Acad Dermatol. 2018;79(5):899-903.
Taylor EM, Boyer K, Campbell FA. Pain in hospitalized children: a prospective cross-sectional survey of pain prevalence, intensity, assessment and management in a Canadian pediatric teaching hospital. Pain Res Manag. 2008;13(1):25-32.
Goss JA, Konczyk DJ, Alomari MH, Maclellan RA, Greene AK. Propranolol treatment of vascular anomalies other than infantile hemangioma. J Craniofac Surg. 2017;28(8):2001-2003.
Scorletti F, Hammill A, Patel M, Ricci K, Dasgupta R. Malignant tumors misdiagnosed as benign vascular anomalies. Pediatr Blood Cancer. 2018;65(7):e27051.